Dan Leonard
Stock Analyst at UBS
(3.85)
# 631
Out of 4,931 analysts
296
Total ratings
53.33%
Success rate
7.4%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CERT Certara | Maintains: Buy | $18 → $15 | $11.23 | +33.57% | 10 | Aug 7, 2025 | |
| MEDP Medpace Holdings | Downgrades: Sell | $300 → $305 | $426.91 | -28.56% | 2 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $460 → $500 | $453.94 | +10.15% | 17 | Jul 24, 2025 | |
| DHR Danaher | Maintains: Buy | $240 → $225 | $198.15 | +13.55% | 18 | Jul 23, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $185 → $225 | $177.04 | +27.09% | 15 | Jul 23, 2025 | |
| MTD Mettler-Toledo International | Upgrades: Buy | $1,530 → $1,350 | $1,224.46 | +10.25% | 9 | May 20, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $14 → $12 | $12.45 | -3.61% | 5 | May 13, 2025 | |
| TECH Bio-Techne | Maintains: Buy | $95 → $70 | $49.50 | +41.41% | 11 | May 9, 2025 | |
| BRKR Bruker | Maintains: Neutral | $57 → $45 | $30.63 | +46.91% | 11 | May 8, 2025 | |
| BIO Bio-Rad Laboratories | Maintains: Buy | $355 → $310 | $262.15 | +18.25% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $247.05 | +25.48% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $70 | $49.74 | +40.73% | 9 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $85.78 | +34.06% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $93.25 | +6.17% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $11.25 | +122.22% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $149.77 | +23.52% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $8.40 | +7.14% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $20.09 | +74.22% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $113.46 | +32.21% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $94.41 | +111.84% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $2.01 | +447.26% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $136.66 | -48.78% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $90 | $41.09 | +119.03% | 9 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $12.24 | -42.81% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $278.18 | +24.02% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $157.75 | +64.82% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $173.51 | -16.43% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $67.74 | +32.86% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $47.97 | +32.69% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $259.41 | +31.07% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $24.26 | -1.07% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $5.89 | +494.73% | 12 | Aug 14, 2019 |
Certara
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $11.23
Upside: +33.57%
Medpace Holdings
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $426.91
Upside: -28.56%
Thermo Fisher Scientific
Jul 24, 2025
Maintains: Neutral
Price Target: $460 → $500
Current: $453.94
Upside: +10.15%
Danaher
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $198.15
Upside: +13.55%
IQVIA Holdings
Jul 23, 2025
Maintains: Buy
Price Target: $185 → $225
Current: $177.04
Upside: +27.09%
Mettler-Toledo International
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,224.46
Upside: +10.25%
10x Genomics
May 13, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $12.45
Upside: -3.61%
Bio-Techne
May 9, 2025
Maintains: Buy
Price Target: $95 → $70
Current: $49.50
Upside: +41.41%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $57 → $45
Current: $30.63
Upside: +46.91%
Bio-Rad Laboratories
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $262.15
Upside: +18.25%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $247.05
Upside: +25.48%
May 1, 2025
Maintains: Buy
Price Target: $65 → $70
Current: $49.74
Upside: +40.73%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $85.78
Upside: +34.06%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $93.25
Upside: +6.17%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $11.25
Upside: +122.22%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $149.77
Upside: +23.52%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $8.40
Upside: +7.14%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $20.09
Upside: +74.22%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $113.46
Upside: +32.21%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $94.41
Upside: +111.84%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $2.01
Upside: +447.26%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $136.66
Upside: -48.78%
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $41.09
Upside: +119.03%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $12.24
Upside: -42.81%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $278.18
Upside: +24.02%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $157.75
Upside: +64.82%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $173.51
Upside: -16.43%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $67.74
Upside: +32.86%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $47.97
Upside: +32.69%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $259.41
Upside: +31.07%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $24.26
Upside: -1.07%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $5.89
Upside: +494.73%